[go: up one dir, main page]

AR051754A1 - Metodos para preparar compuestos de indazol - Google Patents

Metodos para preparar compuestos de indazol

Info

Publication number
AR051754A1
AR051754A1 ARP050104568A ARP050104568A AR051754A1 AR 051754 A1 AR051754 A1 AR 051754A1 AR P050104568 A ARP050104568 A AR P050104568A AR P050104568 A ARP050104568 A AR P050104568A AR 051754 A1 AR051754 A1 AR 051754A1
Authority
AR
Argentina
Prior art keywords
prepare
methods
compound
formula
indazol
Prior art date
Application number
ARP050104568A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR051754A1 publication Critical patent/AR051754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente se refiere a la preparacion de compuestos intermedios utiles como moduladores y/o inhibidores de proteínas quinasas. Reivindicacion 1: Un método para preparar un compuesto de formula (1) o una de sus sales o solvatos farmacéuticamente aceptable, comprendiendo el método hacer reaccionar un compuesto de formula (2) con un compuesto de formula (3) para formar el compuesto de formula (1).
ARP050104568A 2004-11-02 2005-11-01 Metodos para preparar compuestos de indazol AR051754A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
AR051754A1 true AR051754A1 (es) 2007-02-07

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104568A AR051754A1 (es) 2004-11-02 2005-11-01 Metodos para preparar compuestos de indazol

Country Status (14)

Country Link
US (1) US7232910B2 (es)
EP (1) EP1809621A1 (es)
JP (1) JP2008518900A (es)
KR (1) KR20070058690A (es)
AR (1) AR051754A1 (es)
AU (1) AU2005300310A1 (es)
BR (1) BRPI0518203A2 (es)
CA (1) CA2586174A1 (es)
IL (1) IL182693A0 (es)
MX (1) MX2007005291A (es)
NO (1) NO20071619L (es)
RU (1) RU2007116107A (es)
TW (1) TWI294421B (es)
WO (1) WO2006048744A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134702B2 (en) * 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
JP5719781B2 (ja) * 2009-01-08 2015-05-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ３−（１−｛３−［５−（１−メチル−ピペリジン−４−イルメトキシ）−ピリミジン−２−イル］−ベンジル｝−６−オキソ−１，６−ジヒドロ−ピリダジン−３−イル）−ベンゾニトリル塩酸塩の新規な多形体およびその製法
US20140248347A1 (en) 2011-09-30 2014-09-04 Pfizer Inc. Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
US9205078B2 (en) 2011-11-11 2015-12-08 Pfizer Inc. N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
HRP20192183T1 (hr) * 2013-12-06 2020-02-21 Vertex Pharmaceuticals Inc. Spoj 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida koristan kao inhibitor atr kinase, njegova priprava, različiti kruti oblici te njegovi radioaktivno označeni derivati
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
EP3127900B1 (en) * 2014-03-31 2017-10-18 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3956321B1 (en) 2019-04-18 2024-03-20 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
JP2006522087A (ja) * 2003-04-03 2006-09-28 ファイザー・インク Ａｇ０１３７３６を含んでなる剤形
US20080274192A1 (en) 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor

Also Published As

Publication number Publication date
CA2586174A1 (en) 2006-05-11
EP1809621A1 (en) 2007-07-25
IL182693A0 (en) 2007-09-20
TW200621721A (en) 2006-07-01
TWI294421B (en) 2008-03-11
RU2007116107A (ru) 2008-11-10
MX2007005291A (es) 2007-07-19
US7232910B2 (en) 2007-06-19
AU2005300310A1 (en) 2006-05-11
NO20071619L (no) 2007-04-25
JP2008518900A (ja) 2008-06-05
US20060094881A1 (en) 2006-05-04
BRPI0518203A2 (pt) 2009-03-10
WO2006048744A1 (en) 2006-05-11
KR20070058690A (ko) 2007-06-08

Similar Documents

Publication Publication Date Title
AR051754A1 (es) Metodos para preparar compuestos de indazol
AR061980A1 (es) Acilanilidas sustituidas y metodos para su utilizacion
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
SE0301372D0 (sv) Novel compounds
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EA200970856A1 (ru) Ингибиторы пути хеджхога
SE0400284D0 (sv) Novel compounds
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
ECSP088296A (es) Compuestos terapéuticos
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
AU2012248061C1 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure